

1/3
SEQUENCE LISTING

<110> Huang, Mallen

<120> Nucleotide and cellular vaccine composition

<130> P366PC00

<150> SE 0301109-5

<151> 2003-04-14

<160> 7

<170> PatentIn version 3.1

<210> 1

<211> 67

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 1
tgctagcatg atctggccca acgacggcga gggcgccctc cacggcgacg ccgagggccct 60
gcagcgc 67

<210> 2

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 2
aatcgatcac aggccctggg gctcgaagtc gctggccacg gggcgctgca gggc 54

<210> 3

2/3

<211> 96

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(96)

<223>

<400> 3

atg	atc	tgg	ccc	aac	gac	ggc	gag	ggc	gcc	ttc	cac	ggc	gac	gcc	gag	48
Met	Ile	Trp	Pro	Asn	Asp	Gly	Glu	Gly	Ala	Phe	His	Gly	Asp	Ala	Glu	
1				5				10					15			

gcc	ctg	cag	cgc	ccc	gtg	gcc	agc	gac	ttc	gag	ccc	cag	ggc	ctg	tga	96
Ala	Leu	Gln	Arg	Pro	Val	Ala	Ser	Asp	Phe	Glu	Pro	Gln	Gly	Leu		
			20					25					30			

<210> 4

<211> 31

<212> PRT

<213> Homo sapiens

<400> 4

Met	Ile	Trp	Pro	Asn	Asp	Gly	Glu	Gly	Ala	Phe	His	Gly	Asp	Ala	Glu
1				5				10					15		

Ala	Leu	Gln	Arg	Pro	Val	Ala	Ser	Asp	Phe	Glu	Pro	Gln	Gly	Leu
			20					25					30	

<210> 5

<211> 9

<212> PRT

<213> Homo sapiens

<400> 5

Ala	Phe	His	Gly	Asp	Ala	Glu	Ala	Leu
1				5				

<210> 6

<211> 9

3/3

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide with low binding to mouse MHC-I antigen (H-2Kd)

<400> 6

His Gly Asp Ala Glu Ala Leu Gln Arg
1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide that does not bind to mouse MHC-I antigen (H-2Kd)

<400> 7

Ala Thr Gly Phe Lys Gln Ser Ser Lys
1 5